Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Med Chem ; 48(3): 832-8, 2005 Feb 10.
Artigo em Inglês | MEDLINE | ID: mdl-15689167

RESUMO

The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier (BBB) permeability. Specifically, a taxane analogue, Tx-67, with a succinate group added at the C10 position of Taxol, was synthesized and identified as such a candidate. In comparison studies, Tx-67 had no apparent interactions with Pgp, as demonstrated by the lack of enhanced uptake of rhodamine 123 by brain microvessel endothelial cells (BMECs) in the presence of the agent. By contrast, Taxol exposure substantially enhanced rhodamine 123 uptake by BMECs through inhibition of Pgp. The transport across BMEC monolayers was polarized for both Tx-67 and Taxol with permeation in the apical to basolateral direction greater for Tx-67 and substantially reduced for Taxol relative to basolateral to apical permeation. Taxol and cyclosporin A treatments also did not enhance Tx-67 permeation across BMEC monolayers. In an in situ rat brain perfusion study, Tx-67 was demonstrated to permeate across the BBB at a greater rate than Taxol. These results demonstrate that the Taxol analogue Tx-67 had a reduced interaction with Pgp and, as a consequence, enhanced permeation across the blood-brain barrier in vitro and in situ.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Antineoplásicos/síntese química , Barreira Hematoencefálica/efeitos dos fármacos , Paclitaxel/análogos & derivados , Paclitaxel/síntese química , Animais , Antineoplásicos/química , Antineoplásicos/farmacocinética , Barreira Hematoencefálica/metabolismo , Encéfalo/irrigação sanguínea , Encéfalo/metabolismo , Células Endoteliais/metabolismo , Endotélio Vascular/citologia , Endotélio Vascular/metabolismo , Técnicas In Vitro , Masculino , Microcirculação , Paclitaxel/química , Paclitaxel/farmacocinética , Permeabilidade , Ratos , Ratos Sprague-Dawley , Rodamina 123/farmacocinética , Relação Estrutura-Atividade
2.
J Mol Neurosci ; 20(3): 339-43, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14501017

RESUMO

The blood-brain barrier (BBB) effectively prevents microtubule (MT)-stabilizing drugs from readily entering the central nervous system (CNS). A major limiting factor for microtubule-stabilizing drug permeation across the BBB is the active efflux back into the circulation by the overexpression of the multidrug-resistant gene product 1 (MDR1) or P-glycoprotein (P-gp). This study has focused on strategies to overcome P-gp-mediated efflux of Taxol analogs, MT-stabilizing agents that could be used to treat brain tumors and, potentially, neurodegenerative diseases such as Alzheimer's disease. However, taxol is a strong P-gp substrate that limits its distribution across the BBB and therapeutic potential in the CNS. We have found that addition of a succinate group to the C-10 position of paclitaxel (Taxol) results in an agent, Tx-67, with reduced interactions with P-gp and enhanced permeation across the BBB in both in vitro and in situ models. Our studies demonstrate the feasibility of making small chemical modifications to Taxol to generate analogs with reduced affinity for the P-gp but retention of MT-stabilizing properties, i.e., a taxane that may reach and treat therapeutic targets in the CNS.


Assuntos
Barreira Hematoencefálica/efeitos dos fármacos , Neoplasias Encefálicas/tratamento farmacológico , Células Endoteliais/efeitos dos fármacos , Doenças Neurodegenerativas/tratamento farmacológico , Taxoides/química , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/efeitos dos fármacos , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Animais , Sítios de Ligação/efeitos dos fármacos , Sítios de Ligação/fisiologia , Barreira Hematoencefálica/fisiologia , Células Cultivadas , Relação Dose-Resposta a Droga , Sistemas de Liberação de Medicamentos/métodos , Desenho de Fármacos , Células Endoteliais/metabolismo , Masculino , Microtúbulos/efeitos dos fármacos , Microtúbulos/metabolismo , Conformação Molecular , Emaranhados Neurofibrilares/efeitos dos fármacos , Emaranhados Neurofibrilares/metabolismo , Paclitaxel/análogos & derivados , Paclitaxel/química , Ratos , Ratos Sprague-Dawley , Rodamina 123 , Ácido Succínico/química , Ácido Succínico/farmacologia , Taxoides/farmacologia
3.
J Mol Neurosci ; 19(1-2): 101-5, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12212764

RESUMO

Based on microtubule (MT) disruption observed in primary neurons exposed to fibrillar amyloid peptides (A beta), we tested the potential protective effect of MT-stabilizing drugs such as Taxol against A beta-induced disruption of the cytoskeleton. Although Taxol was strongly protective, the fact that it does not cross the blood brain barrier (BBB) led us to synthesize and test other agents with MT-stabilizing properties and possible penetration into the brain. Our studies have thus far demonstrated that several MT-stabilizing agents, including some with structures quite different from that of Taxol, showed significant protective effects. However, not all agents that promoted MT-assembly were protective, suggesting additional mechanisms are involved in the actions of the drugs. A small number of neuroprotective compounds appear to have potential to enter the brain and thus might be tested to see if they slow progression of neurodegeneration in an appropriate animal model of Alzheimer's disease.


Assuntos
Peptídeos beta-Amiloides/toxicidade , Microtúbulos/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/farmacologia , Paclitaxel/farmacologia , Doença de Alzheimer/tratamento farmacológico , Animais , Barreira Hematoencefálica , Morte Celular/efeitos dos fármacos , Células Cultivadas , Citoesqueleto/efeitos dos fármacos , Microtúbulos/patologia , Neurônios/patologia , Fármacos Neuroprotetores/síntese química , Fármacos Neuroprotetores/uso terapêutico , Ratos
4.
Bioorg Med Chem Lett ; 16(3): 495-8, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16289636

RESUMO

A single-site modification of paclitaxel analogs at the C10 position on the baccatin III core that reduces interaction with P-glycoprotein in bovine brain microvessel endothelial cells is described. Modification and derivatization of the C10 position were carried out using a substrate controlled hydride addition to a key C9 and C10 diketone intermediate. The analogs were tested for tubulin assembly and cytotoxicity, and were shown to retain potency similar to paclitaxel. P-glycoprotein interaction was examined using a rhodamine assay and it was found that simple hydrolysis or epimerization of the C10 acetate of paclitaxel and Taxol C can reduce interaction with the P-glycoprotein transporter that may allow for increased permeation of taxanes into the brain.


Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/metabolismo , Alcaloides/química , Encéfalo/citologia , Células Endoteliais/metabolismo , Paclitaxel/química , Taxoides/química , Alcaloides/farmacologia , Animais , Antineoplásicos/química , Antineoplásicos/farmacologia , Bovinos , Interações Medicamentosas , Feminino , Microcirculação , Paclitaxel/farmacologia , Permeabilidade , Rodaminas/metabolismo , Taxoides/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA